comparemela.com

Page 17 - Dewe Rogerson News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Investegate |Hotel Chocolat Group Announcements | Hotel Chocolat Group: PDMR Dealing

A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;

Investegate |Hotel Chocolat Group Announcements | Hotel Chocolat Group: Total Voting Rights

A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;

Sosei Heptares to receive US$2 5 million milestone payment from Formosa Pharmaceuticals

Share this article Share this article TOKYO and CAMBRIDGE, England, March 11, 2021 /PRNewswire/ Sosei Group Corporation ( the Company ) (TSE: 4565) announces that Formosa Pharmaceuticals, Inc. ( Formosa ) has dosed the first patient in a 370-patient randomized Phase 3 clinical trial of APP13007 in the United States (ClinicalTrials.gov Identifier: NCT04739709). APP13007 is a nanoparticle formulation of a steroid in development for the treatment of inflammation and pain after cataract surgery. The milestone has triggered a US$2.5 million payment to Sosei Heptares from Formosa. APP13007 was originally designed and developed at Activus Pharma Inc. ( Activus ), formerly a wholly owned subsidiary of the Company. Activus was divested in August 2017 to Formosa, a wholly owned subsidiary of Formosa Laboratories, Inc., a leading manufacturer of Active Pharmaceutical Ingredients ( APIs ) listed on the Taiwan Stock Exchange. The divestment was part of Sosei Heptares redirected growth stra

Sosei : Heptares to receive US$2 5 million milestone payment from Formosa Pharmaceuticals

Sosei : Heptares to receive US$2 5 million milestone payment from Formosa Pharmaceuticals
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Investegate |Hotel Chocolat Group Announcements | Hotel Chocolat Group: PDMR Dealing

Investegate |Hotel Chocolat Group Announcements | Hotel Chocolat Group: PDMR Dealing
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.